CONCLUSION
This study proved the efficiency of pharmaceutical interviews in
hypertension, type 2 diabetes and hypercholesterolemia, by doubling the
proportion of patients reaching the therapeutic objectives after three
months of a drug therapy. It also made possible to define preferential
populations to benefit from these interventions, such as polypharmacy
and type 2 diabetic patients.
However, further studies with larger samples are needed to conclude on
an effect of the rest of the criteria such as multiple pathologies.
Besides, some studies reported a temporary and short-term effect of this
type of intervention[12,63]. We have deliberately limited this study
to a single intervention and its evaluation after 3 months. Thus,
further studies should focus on this effect on the long term, as well as
the need for repeated pharmaceutical interventions several times a year,
in person or by telephone[54]. In the same way, multicentric
studies, will have to be conducted to refine our results. Moreover, we
stayed focused on the clinical outcomes of these interventions, and we
did not studied the benefits in terms of medicoeconomy and public health
outcomes. Thus, further studies assessing the pharmaceutical costs of
these interviews as well as the impact in terms of hospitalization, are
necessary to evaluate the cost-benefit balance and the public health
impact and have a comprehensive view of all the consequences of
implementing such practices in routine.
This study confirms the interest of clinical pharmacy and of the
evolution of pharmacists’ activities, such as medication
reconciliation[66] and optimized medication reviews, experimented in
community pharmacies since March 2018.